Drugs / GW274150
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00273013 | Nov 2004 → Oct 2005 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00379990 | Jan 2006 → Dec 2007 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00319137 | Dec 2005 → ? | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00242866 | Oct 2005 → Sep 2007 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00370435 | Aug → Sep 2005 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW274150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00379990 ↗ |
| Action | Inhibit | “GW274150 is a highly selective inhibitor of NOS” NCT00242866 ↗1“Nitric oxide synthase, inducible inhibitor” CHEMBL114551 ↗ |
| Modality | Small molecule | — CHEMBL114551 ↗ |
| Route | Oral | “28 days repeat daily oral dosing of 60 mg of the inducible nitric oxide synthase inhibitor GW274150 or 7.5 mg prednisolone in RA.” PMID 22409880 ↗ Apr 2012 |
| Target | NOS2 | “Nitric oxide synthase, inducible inhibitor” CHEMBL114551 ↗ |